Craig R. Rush

Craig R. Rush

Auto-generated profile, based on publicly available information

Craig R. Rush

Department of Behavioral Science, College of Medicine, University of Kentucky, Lexington, USA

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2001 in Journal of Clinical Psychopharmacology
Verified
Journal Article
Closed access
CRCraig R. Rush
Craig R. Rush
WEWilliam D. Essman
William D. Essman
CSCathy A. Simpson
Cathy A. Simpson
RBRobert W. Baker
Robert W. Baker
The reinforcing effects of methylphenidate (20– 40 mg), d-amphetamine (10–20 mg), and placebo were assessed in eight healthy, non–sleep-deprived, non–drug-abusing outpatient volunteers. A modified progressive-ratio schedule was used to assess drug reinforcement in which a sampling session always preceded a self-administration session. During sampling sessions, volunteers received a drug dose to acquaint them with the drug effects. Drug doses were administered in eight identical capsules (i.e., each capsule contained 12.5% of the total dose). During self-administration sessions, which generally were conducted the next day, volunteers were given eight opportunities to work on a computer and could earn all, or some, of the capsules that were administered the previous day. To earn the first capsule, volunteers had to click a computer mouse 50 times. The number of clicks required to earn each additional capsule doubled (i.e., 100, 200, 400, 800, 1,600, 3,200, and 6,400 clicks). The dependent measure on this task was the break point (i.e., the last ratio completed). To characterize more fully the behavioral effects of methylphenidate and d-amphetamine, a battery of subject-rated drug-effect questionnaires, performance tasks, and physiologic measures was also used. Both doses of d-amphetamine increased the break point significantly above placebo levels, whereas only the high dose of methylphenidate did so. Break-point values for the doses of methylphenidate and d-amphetamine that maintained the greatest responding did not differ significantly. Methylphenidate and d-amphetamine produced some stimulantlike subject-rated drug effects (e.g., increased ratings of “drug liking”). These data suggest that methylphenidate, like d-amphetamine, can function as a reinforcer under a modified progressive-ratio schedule and, by inference, has at least some abuse potential in healthy, non–sleep-deprived, non–drug-abusing volunteers.

1 July 2003 in The Journal of Pharmacology and Experimental Therapeutics
Verified
Journal Article
Closed access
PDF file
CRCraig R. Rush
Craig R. Rush
WSWilliam W Stoops
William W Stoops
LHLon R. Hays
Lon R. Hays
PGPaul E. A. Glaser
Paul E. A. Glaser
LHLon S. Hays
Lon S. Hays
Studies conducted with nonhuman laboratory animals have consistently shown that atypical antipsychotics that are mixed dopamine and serotonin antagonists attenuate the discriminative-stimulus effects of amphetamine. In the present experiment, eight healthy humans learned to discriminate 15 mg of oral d-amphetamine. After acquiring the discrimination (i.e., ≥80% correct responding on four consecutive days), the effects of a range of doses of d-amphetamine (0, 2.5, 5, 10, and 15 mg), alone and after pretreatment with risperidone (0 and 1 mg), a D2 dopamine and 5-hydroxytryptamine (5-HT)2 serotonin antagonist, were assessed. d-Amphetamine alone functioned as a discriminative stimulus and produced stimulant-like self-reported drug effects (e.g., increased ratings of “like drug”). These effects were generally a function of dose. Risperidone alone did not occasion d-amphetamine-appropriate responding, but impaired performance. Risperidone pretreatment significantly attenuated the discriminative-stimulus effects of d-amphetamine, and some of the self-reported drug effects. The results of the present experiment suggest that combining drug-discrimination and self-reported drug-effect questionnaires may be an effective strategy for assessing the behavioral effects of agonist-antagonist interactions. Future studies should compare the behavioral effects of d-amphetamine after pretreatment with a selective D2 dopamine (e.g., haloperidol) or 5-HT2 serotonin (e.g., ritanserin) antagonist to determine the relative contribution of dopamine and serotonin systems in mediating the behavioral effects of stimulants in humans. The results of these studies might guide the development of a pharmacotherapy for the treatment of amphetamine abuse/dependence.

1 March 2002 in Behavioural Pharmacology
Verified
Journal Article
Closed access
CRC.R. Rush
C.R. Rush
TKT.H. Kelly
T.H. Kelly
LHL.R. Hays
L.R. Hays
RBR.W. Baker
R.W. Baker
AWA.F. Wooten
A.F. Wooten
Modafinil, a novel stimulant, is effective in the treatment of excessive daytime sleepiness associated with narcolepsy. It is biochemically and pharmacologically distinct from prototypical stimulants such as D-amphetamine, cocaine, and methylphenidate. The present experiment was designed to assess the acute behavioral effects of oral modafinil, cocaine, and placebo in participants (n =9) with recent histories of cocaine use (i.e. positive urine for cocaine or benzoylecgonine during the initial screening interview). Drug effects were assessed with a battery of self-reported drug-effect questionnaires, performance measures, and physiological indices. Cocaine, but not modafinil, produced stimulant-like self-reported drug effects (e.g. increased ratings of High and Stimulated). Modafinil and cocaine dose-dependently increased heart rate and blood pressure. The results of the present study suggest that modafinil has minimal abuse potential, but should be viewed cautiously because of the relatively small sample size. Future studies should further characterize the abuse potential of modafinil using other behavioral arrangements, such as drug discrimination or drug self-administration. A full characterization of the abuse potential of modafinil will become important as the use of this drug increases.

29 June 2005 in Psychopharmacology
Verified
Journal Article
Closed access
PDF file
WSWilliam W Stoops
William W Stoops
JLJoshua A. Lile
Joshua A. Lile
MFMark T. Fillmore
Mark T. Fillmore
PGPaul E. A. Glaser
Paul E. A. Glaser
CRCraig R. Rush
Craig R. Rush

1 January 2001 in Experimental and Clinical Psychopharmacology
Verified
Journal Article
Closed access
CRCraig R. Rush
Craig R. Rush
RBRobert W. Baker
Robert W. Baker
Six human participants with recent histories of cocaine use were trained to discriminate 200 mg oral cocaine hydrochloride. A range of doses of oral cocaine (50-300 mg), methylphenidate (15-90 mg), triazolam (0.125-0.75 mg), and placebo were then tested to determine whether they shared discriminative-stimulus and participant-rated effects with 200 mg cocaine. Cocaine and methylphenidate dose-dependently increased cocaine-appropriate responding, produced prototypical stimulant-like participant-rated drug effects (e.g., increased participant ratings of Drug Liking), and increased heart rate and blood pressure. Triazolam produced low levels of cocaine-appropriate responding and impaired performance. Thus, consistent with previous studies, humans can reliably discriminate oral cocaine. Consistent with in vivo behavioral neuropharmacological data, the discriminative-stimulus, participant-rated, and physiological effects of oral cocaine and methylphenidate were similar.

1 August 2002 in Drug and Alcohol Dependence
Verified
Journal Article
Closed access
CRCraig R Rush
Craig R Rush
TKThomas H Kelly
Thomas H Kelly
LHLon R Hays
Lon R Hays
AWAdam F Wooten
Adam F Wooten